RAPT Therapeutics Inc(RAPT) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -11.07 | Insider Own | 48.8% | Shs Outstand | 16.9M | Perf Week | - |
| Market Cap | 1.61B | Forward P/E | - | EPS next Y | -44.51% | Insider Trans | - | Shs Float | 14.2M | Perf Month | 0.52% |
| Enterprise Value | 1.45B | PEG | - | EPS next Q | -0.81 | Inst Own | 66.35% | Short Float | 9.44% | Perf Quarter | 58.44% |
| Income | -0.11B | P/S | - | EPS this Y | 92.17% | Inst Trans | - | Short Ratio | 0.51 | Perf Half Y | 269.55% |
| Sales | 0.00B | P/B | 6.43 | EPS next 5Y | 47.76% | ROA | -77.05% | Short Interest | 1.34M | Perf YTD | 71.3% |
| Book/sh | 9.02 | P/C | 10.22 | EPS past 3/5Y | -8.04% -10.1% | ROE | -85.37% | 52W High | 0% ($58.02) | Perf Year | 536.18% |
| Cash/sh | 5.68 | P/FCF | - | Sales past 3/5Y | - | ROIC | -69.33% | 52W Low | 924.15% ($5.67) | Perf 3Y | -75.42% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 50.23% | Gross Margin | - | Volatility(W/M) | 0.08% 0.19% | Perf 5Y | -58.77% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.56 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 12.04 | EPS Q/Q | 82.8% | Profit Margin | - | RSI (14) | 79.17 | Recom | 3 |
| Dividend Gr. 3/5Y | - | Current Ratio | 12.04 | Sales Q/Q | - | SMA20 | 0.34% ($57.82) | Beta | 0.45 | Target Price | $58 |
| Payout | - | Debt/Eq | 0.02 | Earnings | 11000000 | SMA50 | 21.76% ($47.65) | Rel Volume | 0 | Prev Close | $58.02 |
| Employees | 68 | LT Debt/Eq | 0 | EPS/Sales Surpr. | 33.54% - | SMA200 | 126.76% ($25.59) | Avg Volume(3M) | 2.62M | Price | $58.02 |
| IPO | 2019/10/31 | Option/Short | Yes/No | Trades | 0 | Volume | - | Change | - |
A biotech developing treatments for immune-inflammatory diseases. Its lead candidate is ozureprubart, an IgE antibody. Q3 2025 showed an improved net loss and the company maintains a sufficient cash position. An acquisition by GSK is currently in progress.
Over the past 1 year, on the higher side
0% below its 1-year high.
Traded less than usual. That is 0% of its average volume.
RAPT has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +92.2% this year.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Hold.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -58.8%. The S&P 500 did +62% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership looks stable
Institutions hold 66.3%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #121 of 598 in the industry
Based on market cap of $2B.
RARE#119 Ultragenyx Pharmaceutical Inc $2B PER - 
PGEN#120 Precigen Inc $2B PER 101.1 RAPT#121 RAPT Therapeutics Inc $2B PER - 
QURE#121 uniQure NV $2B PER - 
NTLA#122 Intellia Therapeutics Inc $2B PER - 
FAQ
What kind of company is RAPT?
RAPT belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of RAPT?
The market cap of RAPT is approximately $1.6B, ranking 2,175 within its sector.
What is the 52-week high and low for RAPT?
RAPT has recorded a 52-week high of $58.02 and a low of $5.67.
